Bioventus Inc

Bioventus insider buying signals confidence in bone‑healing trials and future FDA approval, offering investors a bullish outlook on a niche biotech player.

Bioventus insider sale: Michelle McMurry‑Heath sold 12,000 shares at $8.79, a routine liquidity move that highlights the firm’s steady growth outlook and regulatory focus.

Mark Leonard’s 7.2% equity boost at Bioventus signals confidence amid high P/E and FDA‑approval pressure—investors weigh growth potential vs. valuation risk.